Nuage Therapeutics is a biotech company focused on developing small molecule inhibitors of oncogenic transcription factors. The company has a particular focus on drugging cell lineage-specific transcription factors that are known cancer dependency genes. Built on a deep understanding of transcriptional regulation and the biophysics of intrinsically-disordered proteins (IDPs), Nuage has developed technologies that enable the ‘capture’ of IDPs in higher-order, self-assembled states that present binding pockets that render these proteins amenable to small molecule drug discovery. This represents a game-changing advance that has led to the identification of functional inhibitors of multiple transcription factors that were previously considered undruggable.
Company Details
- Employees
- 25
- Founded
- -
- Address
- Carrer Baldiri Reixac, 4-8,spain
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://nuagetx.com
- HQ
- Barcelona
Nuage Therapeutics Questions
Nuage Therapeutics's website is https://nuagetx.com
Nuage Therapeutics's LinkedIn profile is https://es.linkedin.com/company/nuagetx
Nuage Therapeutics has
25 employees.
View email and phone details for 25
employees at Nuage Therapeutics.
Nuage Therapeutics's industry is
Biotechnology Research
Nuage Therapeutics's top competitors are
Oryzon Genomics Sa,
Ona Therapeutics,
Splicebio,
Onechain Immunotherapeutics,
Allox,
Aelix Therapeutics,
Minoryx Therapeutics,
Deepull,
Aptadel Therapeutics,
Mimark Diagnostics.
Nuage Therapeutics's categories are Biotechnology Research
Nuage Therapeutics's founding year is 2021
